Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positive early results for Canopus's statin/caffeine flu treatment

This article was originally published in Scrip

Executive Summary

Canopus BioPharma has reported positive preclinical results with StatC, a combination of a statin and caffeine, in the prevention and treatment of H5N1, H1N1 and H3N2 flu infections. In research carried out in collaboration with the Sun Yat-sen University in Guangzhou, China, 50μg of the undisclosed statin compound and 200μg caffeine administered preventatively was found to inhibit lung viral replication and damage in a mouse model, the US firm said. It is now planning further animal testing and is seeking private and government development partners. Statins act to inhibit viral entry by interfering with cholesterol synthesis to reduce the number of cholesterol-rich attachment sites on cell membranes.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC001531

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel